Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Standard Biotools (LAB) Shares Repurchased (2022 - 2024)

Standard Biotools has reported Shares Repurchased over the past 3 years, most recently at $29.4 million for Q2 2024.

Quarterly Shares Repurchased rose 1126.62% to $29.4 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $29.4 million through Mar 2025, up 109.9% year-over-year, with the annual reading at $40.5 million for FY2024, 647.88% up from the prior year.
Shares Repurchased was $29.4 million for Q2 2024 at Standard Biotools, up from $11.1 million in the prior quarter.
Over five years, Shares Repurchased peaked at $29.4 million in Q2 2024 and troughed at $174000.0 in Q4 2023.
The 3-year median for Shares Repurchased is $2.4 million (2023), against an average of $6.6 million.
Year-over-year, Shares Repurchased crashed 69.09% in 2023 and then surged 1126.62% in 2024.
A 3-year view of Shares Repurchased shows it stood at $563000.0 in 2022, then crashed by 69.09% to $174000.0 in 2023, then skyrocketed by 16818.97% to $29.4 million in 2024.
Per Business Quant, the three most recent readings for LAB's Shares Repurchased are $29.4 million (Q2 2024), $11.1 million (Q1 2024), and $174000.0 (Q4 2023).